<PAGE> 1
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
---------------------------------
NOTIFICATION OF LATE FILING SEC FILE NUMBER
0-18976
---------------------------------
---------------------------------
CUSIP NUMBER
151186103
---------------------------------
(Check One)
[X] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q
and Form 10-QSB [ ] Form N-SAR
For Period Ended: March 31, 1999
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________________
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
Part I --Registrant Information
Celtrix Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
Full Name of Registrant
N/A
- --------------------------------------------------------------------------------
Former Name if Applicable
2033 Gateway Place, Suite 600
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
San Jose, CA 95110
- --------------------------------------------------------------------------------
City, State and Zip Code
<PAGE> 2
Part II - Rules 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on
Form 10 K, Form 20-F, 11-K, Form N-SAR, or portion thereof will be
filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof will be filed on
or before the fifth calendar day following the prescribed due date;
and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
Part III - Narrative
State below in reasonable detail the reasons why the Form 10-K and Form 10-KSB,
20F, 11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion
thereof, could not be filed within the prescribed period. (Attach Extra Sheets
if Needed)
Registrant was not able to file its Annual Report on Form 10-K for the year
ended March 31, 1999 because its financial audit is not complete.
Part IV - Other Information
(1) Name and telephone number of person to contact in regard to this
notification
Donald D. Huffman (408) 988-2500
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of
the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was
required to file such report(s) been filed?
If answer is no, identify report(s).
X Yes No
--- -----
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or
portion thereof? Yes X No
--- ---
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
<PAGE> 3
CELTRIX PHARMACEUTICALS, INC.
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: June 29, 1999 By /s/Donald D. Huffman
-------------------------------
Donald D. Huffman
Vice President, Finance and Administration,
Chief Financial Officer and Assistant
Secretary (Principal Financial and
Accounting Officer)
